Entries |
Document | Title | Date |
20080214490 | METHOD OF PROMOTING CERVICAL AND VAGINAL SECRETIONS - The present invention provides a method of stimulating cervical and vaginal secretions in a mammal by treatment with P2Y | 09-04-2008 |
20080249060 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION - Disclosed are compounds, compositions and methods for treating hepatitis C virus infections. | 10-09-2008 |
20080261913 | Compounds and pharmaceutical compositions for the treatment of liver disorders - Provided herein are compounds, compositions and methods for the treatment of liver disorders, including liver cancer and metabolic diseases, such as diabetes, hyperlipidemia, atherosclerosis, and obesity. Specifically, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-cancer agents. | 10-23-2008 |
20080287391 | Cell Fusion Promoter and Utilization of the Same - It is intended to provide a regeneration promoter for regenerating a tissue with the use of somatic stem cells. It is also intended to provide a cell fusion promoter safely usable in vivo. Namely, it is intended to provide a cell fusion promoter comprising ATP or its metabolite. A cell fusion promoter comprising ATP or its metabolite and a method of producing fused cells in the presence of ATP or its metabolite. A medicinal composition for regenerating or improving the function of a tissue or an organ, which suffers from dysfunction or hypofunction due to injury or denaturation, by using stem cells. This composition comprises ATP or its metabolite and a pharmaceutically acceptable carrier. | 11-20-2008 |
20080293665 | Purine Nucleotide Derivatives - This invention provides novel 8-carbyl substituted Camps (adenosine 3′,5′-cyclic monophosphorothioate) and a novel procedures for the preparation of 8-Br-cAMP, a key starting material. | 11-27-2008 |
20080293666 | Antibacterial Agents - The invention provides compounds of formula (I) and salts thereof: R | 11-27-2008 |
20080300215 | Prodrugs Activated by Rna-Dependent Dna-Polymerases - Herein described are prodrugs activated by RNA-dependent DNA-polymerases, such as telomerase and retroviral reverse transcriptases, their use for the treatment of haematological tumours and of blood and blood derivatives from patients affected by retroviral infections, and their use for the preparation of pharmaceutical compositions, to be used for the treatment of solid tumours, of precancerous states and of diseases caused by infection with retroviruses. | 12-04-2008 |
20080312181 | Composition and Methods for Skin Care - Compositions useful in the treatment of skin atrophy and improvement of skin appearance and texture are disclosed. The methods include the topical administration of vitamin D3 or specific vitamin D3 analogs as an essential ingredient either on its own or in combination with cADPR and or nicotinamide. The compositions are particularly effective in preventing and treating signs of chronological and or photoaging including fine lines, wrinkles and discoloration. | 12-18-2008 |
20090082305 | METHOD OF IMPROVING STORAGE STABILITY OF SUBSTANCE - The present invention relates to a method of improving storage stability of reduced form of nicotinamide adenine dinucleotide, reduced form of nicotinamide adenine dinucleotide phosphate, or a salt thereof, or ascorbic acid, an ascorbic acid derivative, or a salt thereof, which comprises allowing the substance to coexist with an L-arginine acidic amino acid salt, a composition containing the substance and an L-arginine acidic amino acid salt, a process for producing the composition, and a method of storing the substance in the presence of an L-arginine acidic amino acid salt. | 03-26-2009 |
20090156545 | Substituted Phosphate Esters of Nucleoside Phosphonates - Compounds and compositions are provided for treatment, prevention, or amelioration of a variety of medical disorders associated with viral infections and/or cell proliferation. The compounds provided herein are obtained by attaching the phosphonate nucleoside of interest to alkyloxyalkyl-phosphate or alkyl-phosphate in a phosphate-phosphono anhydride linkage to provide a modified nucleoside phosphonate drug. | 06-18-2009 |
20090156546 | Compositions and methods for modulating the immune system - The present invention provides methods and compositions for the prophylaxis of blood cell disorders such as neutropenia, thrombocytopenia, lymphocytopenia, and anaemia. The invention provides methods wherein compositions comprising at least one cytokinin compound are administered either therapeutically or prophylactically. The invention further has utility in methods of DNA repair. | 06-18-2009 |
20090192120 | INHIBITORS OF NITRIC OXIDE SYNTHASE - The current invention discloses novel methods for the inhibition of inducible nitric oxide synthesis (iNOS) and the production of NO. Methods of inhibiting the induction of proinflammatory cytokines are also described. Methods of treating various disease states, such as X-linked adrenoleukodystrophy, multiple sclerosis, Alzheimer's and septic shock using inhibitors of iNOS and cytokine induction are disclosed. The inhibitors include the exemplary compounds lovastatin, a sodium salt of phenylacetic acid (NaPA), FPT inhibitor II, N-acetyl cysteine (NAC), and cAMP. | 07-30-2009 |
20090203638 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION - Pharmaceutical compositions include compounds with cytokinin activity to modulate glucose and/or lipid metabolism in a mammal. Especially preferred compounds include those comprising a purine scaffold, and it is further preferred that contemplated compositions are employed to prevent and/or treat various diseases, including pre-diabetes, insulin resistance, type-2 diabetes, Syndrome X, and dyslipidemia. In still further preferred aspects, compounds with cytokinin activity are used to activate AMPK and/or Akt. Consequently, various diseases associated with dysregulation of AMPK and/or Akt may be treated using the compounds of the present inventive subject matter. | 08-13-2009 |
20090209481 | Nucleoside prodrugs and uses thereof - Compounds having the formula I or II wherein R | 08-20-2009 |
20090215713 | Use of atp for the manufacture of a medicament for the prevention and treatment of oxidative stress and related conditions - The present invention provides the use of ATP for the manufacture of a medicine comprising ATP as an active ingredient for exerting a preventive or therapeutic pharmacological effect when administered to a mammal, preferably a human, selected from the group consisting of: a. modulating oxidative stress and the effects thereof by favourably affecting the formation or scavenging of aggressive hydroxyl radicals; b. modulating the inflammatory response to a strong external insult such as endotoxin (LPS) and/or phytohaemagglutinin, even under conditions of severe oxidative stress; c. inhibiting the inflammatory response to a strong external insult such as endotoxin (LPS) and/or phytohaemagglutinin under conditions of severe oxidative stress; d. exerting a local protective effect against oxidative stress in the intestine, thus preventing intestinal damage induced by several types of medication such as non steroid anti-inflammatory drugs (NSAIDs); e. exerting favourable immuno-modulating and oxidative stress-reducing effects in blood from patients with oxidative stress-related disorders; and f. exerting favourable clinical effects in patients with different oxidative stress-related disorders such as, but not limited to, rheumatoid arthritis, intestinal disease, cancer and fatigue. The medicine is preferably manufactured in lyophilized form. | 08-27-2009 |
20090215714 | Pyrimidines, such as cytidine, in treatments for patients with biopolar disorder - The invention is based on the discovery that specific dosages of pyrimidine compositions, such as cytidine compositions, can be used to treat patients diagnosed with bipolar disorder. | 08-27-2009 |
20090215715 | Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer - Phosphoramidate derivatives of nucleoside compounds such as cladribine, isocladribine, fludaribine and clofarabine have enhanced therapeutic potency in | 08-27-2009 |
20090247483 | Method for Treatment of Macular Degeneration - Provided is a method of treating or preventing age-related macular degeneration (AMD) in a patient subject to, or symptomatic of the disease, wherein the method comprises restoring normal lysosomal pH (pH | 10-01-2009 |
20090306006 | USE OF NICOTINIC ACID ADENINE DINUCLEOTIDE PHOSPHATE OR DERIVATIVE THEREOF AS AGENT FOR TREATING TYPE-2 DIABETES - Nicotinic acid adenine dinucleotide phosphate and a pharmaceutically acceptable derivative thereof are useful for the treatment of type-2 diabetes. | 12-10-2009 |
20100004192 | 4'-Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication - The present invention relates to the use of nucleoside derivatives of formula Ia | 01-07-2010 |
20100016250 | TOLL-LIKE RECEPTOR 9 AGONISTS - The present invention provides TLR9 agonists comprising, as an active ingredient, a compound represented by formula (I): | 01-21-2010 |
20100048501 | Phosphorylated A2A Receptor Agonists - A phosphorylated A | 02-25-2010 |
20100048502 | BHQ-CAGED NUCLEOTIDE PROBES PHOTOLYSABLE BY TWO-PHOTON EXCITATION - The disclosure encompasses caged compounds such as caged nucleoside phosphoesters (caged nucleotides). In an embodiment, the caged nucleotides include compounds corresponding to those described by formula (I) that may be activated by two-photon excitation, and methods of synthesis of such compounds. 8-Bromo-7-hydroxyquinoline-caged ATP was synthesized and examined for its photochemistry as a biologically useful, temporally and spatially controlled ATP-releasing reagent. The combination of two-photon excitation hydrolysis and activation of caged ATP enables methods for finely focusing ATP activation at the sub-cellular level or to a greater depth of activation, thereby providing improved resolution of ATP-dependent processes at the cellular level. | 02-25-2010 |
20100081626 | WEIGHT LOSS COMPOSITIONS AND USES THEREOF - This invention provides unique and advantageous formulations and methods for weight loss. | 04-01-2010 |
20100081627 | POLYMERIC NUCLEOSIDE PRODRUGS - Disclosed are polymeric compounds which are useful as prodrugs, comprising a chain of monomeric nucleosides, nucleoside analogs or abasic nucleosides, wherein at least one of the nucleosides or nucleoside analogs or a heterocyclic derivative thereof is pharmaceutically active and the nucleosides, nucleoside analogs or abasic nucleosides are linked by a phosphodiester group, a phosphorothioate group or an H—, alkyl or alkenyl phosphonate group. | 04-01-2010 |
20100113380 | P2X7 ANTAGONISTS TO TREAT AFFECTIVE DISORDERS - The present invention provides methods to treat mood disorders and anxiety disorders using antagonists of the P2X | 05-06-2010 |
20100130438 | METHOD FOR INCREASING OXYTOCIN RELEASE IN THE EPIDERMIS - A method for increasing oxytocin release through direct action on the epidermal keratinocytes is provided. The method for increasing oxytocin release in the epidermis includes increasing the calcium ion concentration in the epidermal cells. In the method of the present invention, the increase of the calcium ion concentration in the epidermal cells may be achieved by physically stimulating the skin. The physical stimulation may be achieved by applying a heat stimulus and/or a massage. The increase of the calcium ion concentration in the epidermal cells may be achieved by stimulating the epidermal cells by at least one agent selected from the group consisting of ATP, UTP, 4 alpha-phorbol 12,13-didecanoate, and pharmaceutically acceptable salts thereof. | 05-27-2010 |
20100137237 | PROCESS FOR THE PREPARATION OF AN (RP)-8-SUBSTITUTED CAMPS - This invention relates to a process for the preparation of an (Rp)-8-substituted adenosine-3′,5′-cyclic phosphorothioic acid, or a salt or ester thereof, which comprises P-amidating 8-bromoadenosine-3′,5′-cyclic phosphoric acid, and reacting the P-amidate with a base and with carbon disulphide to yield (Rp)-8-bromoadenosine-3′,5′-cyclic phosphorothioic acid or a salt or ester thereof. | 06-03-2010 |
20100137238 | Method For Increasing Hair Growth - The present invention provides a method for stimulating hair growth, which comprises applying a composition containing at least one energy-inducing compound selected from the group consisting of 5′-AMP and ATP. Such a composition is particularly effective in increasing the DNA synthesis in dermal papilla cells. | 06-03-2010 |
20100168050 | COMPOUNDS HAVING ANTIANGIOGENIC ACTIVITY - The use of o-ATP as a pharmacological agent useful for the treatment of diseases in whose onset or progression angiogenesis is involved. | 07-01-2010 |
20100216735 | GPCR ENHANCED NEUROPROTECTION TO TREAT BRAIN INJURY - Disclosed are methods of preventing or treating neuronal damage associated with oxidative stress and/or neuronal injury. The method comprises administering to a patient a pharmaceutical composition comprising a purinergic P2Y receptor ligand, in an amount effective to increase the extracellular concentration of said agonist in the brain of the subject such that at least a portion of cell surface P2Y receptors expressed by astrocytes are activated to mount a neuroprotective response. The pharmaceutical composition may be administered orally or parenterally. The pharmaceutical composition with typically be administered to an individual within at least one hour of the event that caused oxidative stress in the subject. The pharmaceutical composition includes a P2Y purinergic receptor agonist, which can include uridine 5′-di- and triphosphate (UDP, UTP) and their analogs, adenosine 5′-diphosphate (ADP) and its analogs, cytidine 5′-di- and triphosphate (CDP, CTP) and their analogs, and dinucleoside polyphosphate compounds. | 08-26-2010 |
20100222294 | Formulations of ATP and Analogs of ATP - This disclosure provides solutions and compositions (e.g., pharmaceutical solutions and compositions) containing adenosine 5′-triphosphate (ATP) or an analog thereof. In addition, it features methods of making and using the solutions and compositions. | 09-02-2010 |
20100249055 | CLOFARABINE PHOSPHOLIPID DERIVATIVES - The subject of the present invention are specific phospholipidesters of clofarabine and the use of such lipidesters in the treatment of tumors. | 09-30-2010 |
20100279972 | COMPOSITION FOR EXTERNAL APPLICATION - A composition for external use capable of more efficiently deriving the effect of purine substances (and/or salts thereof) including (A) sugar; and (B) at least one member selected from the group consisting of purine substances and salts thereof. | 11-04-2010 |
20100286083 | NUCLEOSIDE ANALOGS - A purified compound having activity against hepatitis C virus is disclosed. | 11-11-2010 |
20100311682 | ANTIMELANCHOLIC MEDICINE PREPARED WITH JUJUBE CAMP MATERIALS - The antimelancholic medicine or health products prepared with jujuba cAMP materials and the preparative method are provided in the present invention. | 12-09-2010 |
20100331274 | Antiaging Chirally-Correct Mitoprotectant Amino Acid and Peptide Complexes - This invention relates to certain chirally-correct mitoprotectant phosphorylated heterocyclic agents [formula (I)], which are useful for the treatment of dermatological disorders that include challenged skin from cancer, diabetes, radiation treatments, chemotherapy, and sun-burn; mitochondrial dysfunction; age spots; acne, loss of cellular antioxidants; skin changes associated with aging including collagen loss, loss of skin pliability, loss of skin suppleness, skin wrinkles and fine lines, oxidation, damage from radiation, damage from free radicals, and damage from UV; dry skin; xerosis; ichthyosis; dandruff; brownish spots; keratoses; melasma; lentigines; liver spots; skin pigmentation including pigmented spots, dark circles under the eyes, darkened skin, and blemishes; oily skin; warts; eczema; pruritic skin; psoriasis; inflammatory dermatoses; topical inflammation; disturbed keratinization; scalp dryness; skin depigmentation, and combinations thereof; | 12-30-2010 |
20110003767 | Inhibitors of Acetyl-CoA Carboxylase for Treatment of Neuronal Hypometabolism - This invention relates to methods of using inhibitors of the enzyme acetyl-CoA carboxylase (ACC) for the treatment, prevention, inhibition or alleviation of diseases associated with neuronal hypometabolism and/or loss of cognitive function caused by reduced neuronal metabolism such as, for example, Age Associated Memory Impairment (AAMI), Mild Cognitive Impairment (MCI), Alzheimer's disease, Parkinson's disease, Friedreich's Ataxia (FRDA), GLUT1-deficient Epilepsy, Leprechaunism and Rabson-Mendenhall Syndrome, Coronary Arterial Bypass Graft (CABG) dementia, anesthesia induced memory loss, Huntington's disease and many others. | 01-06-2011 |
20110009356 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS - Novel cyclic phosphoramidate prodrugs of drugs of formula I | 01-13-2011 |
20110028421 | Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals - The invention relates to the use of alkylphosphocholines in combination with antimetabolites for the treatment of multiple myeloma, colon cancer or renal cancer. Preferred alkylphosphocholines are described by the Formula II. | 02-03-2011 |
20110028422 | COMBINATION OF NILOTINIB AND A NITROGEN MUSTARD ANALOGUE FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA - The invention relates to a combination which comprises (a) a DNA damaging agent; and (b) 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide (“nilotinib”); a pharmaceutical composition comprising such a combination and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment chronic lymphocytic leukemia (CLL); the use of such a combination for the preparation of a medicament for the treatment of CLL; a commercial package or product comprising such a combination; and to a method of treatment of a warm-blooded animal, especially a human. | 02-03-2011 |
20110046083 | ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE - The invention described herein features methods, compositions, and kits for the use of activators of PKM2 for the treatment, prevention, or amelioration of diseases related to PKM2 function, including, e.g., cancer, diabetes, atherosclerosis, restenosis, obesity, autoimmune disorders, and proliferative disorders. | 02-24-2011 |
20110059916 | Methods and Compositions for Inducing Torpor in a Subject - The present invention relates to the discovery the 5′-AMP and analogues thereof can be used to induce a state of torpor or suspended animation in subjects, as exemplified by studies carried out in laboratory mice. In these studies; mice were injected with high doses of 5′-AMP, which was found to result in a decoupling of the animals' body temperature regulation mechanism accompanied by a reduction in the animals' core body temperature, which tended to lower towards the ambient environmental temperature. It was further discovered that the introduction of high levels of 5′-AMP resulted in an induction of fat regulation genes such as procolipase (Clps) in tissues and organs that do not normally express Clps, this in turn was accompanied by a shift in metabolism from a primarily glycolytic energy metabolism (which is inhibited at lower temperatures) to one that relied primarily on the liberation and metabolism of free fatty acids. Substantial medical and other applications that arise out of this discovery are also disclosed. | 03-10-2011 |
20110098243 | ECTONUCLEOTIDASE PYROPHOSPHATE/PHOSPHODIESTERASE-1 (ENPP-1) AS A TARGET FOR THE TREATMENT OF AORTIC VALVE STENOSIS AND CARDIOVASCULAR CALCIFICATION - Aortic valve stenosis (AS) is a chronic process related to a progressive mineralization of the aortic root and valve cusps. We found in human AS valves a high level of expression and enzymatic activity of ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP-1), which correlated to the degree of mineralization. In vitro, inhibition of ENPP activity with ARL 67156 significantly reduced calcification of isolated valve interstitial cells. In a rat model of cardiovascular calcification, ARL 67156 significantly reduced calcification of the aortic root and valve cusps. This is the first study to demonstrate that increased expression and activity of ENPP-1 promotes the mineralization process in AS valves. Hence, inhibition of ectonucleotidase may represent a novel target of therapy for this frequent and serious cardiovascular disease. | 04-28-2011 |
20110112045 | CREAMY O/W EMULSION COMPOSITION AND PRODUCTION PROCESS THEREOF - A major object of the present invention is to provide a creamy O/W emulsion composition containing an adenosine phosphate ester, more specifically, to provide a creamy O/W emulsion composition containing an adenosine phosphate ester, which ensures emulsification stability and a superior feel during use. Specifically, the present invention provides a creamy O/W emulsion composition containing the following Components (A) to (F) at the following proportions based on its total amount: | 05-12-2011 |
20110118204 | NUTRITIONAL COMPOSITION WITH FREE AMINO ACIDS AND STRUCTURED LIPIDS - A nutritional composition is proposed, such as an infant formula composition or an enteral composition for children 3-17 years, that is especially targeted as patients having food allergies or impairments of intestinal absorption. The composition comprises structured lipids. The composition is based on free amino acids and contains a very low amount of peptides or proteins, if any. The composition comprises a source of carbohydrate and has a particular caloric density. The composition can comprise arachidonic acid (ARA) and/or docosahexaenoic acid (DHA). The composition delivers specific nutritional benefits to the patients. | 05-19-2011 |
20110124592 | NUCLEOSIDE ARYL PHOSPHORAMIDATES AND THEIR USE AS ANTI-VIRAL AGENTS FOR THE TREATMENT OF HEPATITUS C VIRUS - Phosphoramidate derivatives of nucleoside compounds of formula I derived from bases such as adenine and guanine have enhanced therapeutic potency, in particular, enhanced potency with respect to the prophylaxis or treatment of a viral infection such as hepatitis C virus. The glycoside moiety of the nucleoside compound is suitably substituted at the β-2′ position with methyl and the phosphoramidate group, suitably comprises 1-naphthyl linked by —O— to the P atom. | 05-26-2011 |
20110144050 | SALTS OF HIV INHIBITOR COMPOUNDS - The invention is related to salts of anti-viral compounds, compositions containing such salts, and therapeutic methods that include the administration of such salts, as well as to processes and intermediates useful for preparing such salts. | 06-16-2011 |
20110207690 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS - The present invention provides compositions methods for treating susceptible viral infections, especially hepatitis C viral (HCV) infections as well as co infections of HCV with other viruses such as HBV and/or HIV. In one embodiment, the present invention provides compositions having the formula (I) and their use in treating viral infections: | 08-25-2011 |
20110207691 | COBALAMIN COMPOSITIONS FOR THE TREATMENT OF CANCER - Compositions are provided that contain a combination of a nitric oxide-cobalamin complex along with at least one cobalamin drug conjugate, together with methods for their use in the treatment of neoplastic disease. | 08-25-2011 |
20110212913 | THERAPEUTIC COMPOSITIONS COMPRISING PHENOLIC ACIDS FOR TREATING CONDITIONS RELATED TO INAPPROPRIATE PLATELET AGGREGATION - The invention provides compositions comprising a therapeutically effective amount of a compound of general formula (I): wherein R1, R2 and R3 may be independently selected from H, OH and OMe; wherein X is C | 09-01-2011 |
20110224163 | GEL COMPOSITION FOR EXTERNAL APPLICATION CONTAINING AN ADENINE COMPOUND (As Amended) - An object of the present invention is to provide a composition for external application that is applied to a part of the skin to more effectively elicit the useful effects of an adenine compound such as adenine, adenosine, and a phosphoric ester of adenosine, and that has long-lasting effects and enhanced skin-moisturizing effects. A gel composition for external application containing an adenine compound such as adenine, adenosine, and a phosphoric ester of adenosine is prepared by using agar as a gelling agent. The gel composition is further prepared in the form of a sheet-like adhesive patch. The gel composition in the form of a sheet-like adhesive patch is kept immersed in an aqueous solution containing the adenine compound. | 09-15-2011 |
20110269708 | P2X7 ANTAGONISTS TO TREAT AFFECTIVE DISORDERS - The present invention provides methods to treat mood disorders and anxiety disorders using antagonists of the P2X | 11-03-2011 |
20110288043 | MAINTENANCE OF PLATELET INHIBITION DURING ANTIPLATELET THERAPY - A method of treating or preventing a disease or condition in a subject that was previously treated with at least one thienopyhdine is described. The method includes administering to the subject an effective amount of at least one reversible, short-acting P2Yi2 inhibitor. The described method can be used for subjects diagnosed with symptoms such as stable or unstable angina, vascular ischemic events, atherosclerosis, acute coronary syndrome, as well as STEMi or N-STEMI. The described method can also be used for patients having previously received a stent, such as a bare metal stent or a drug-eluting stent, and the treatment or prevention of stent thrombosis. The method can be used prior to, during, or after an invasive procedure such as coronary artery bypass grafting, percutaneous coronary intervention, or other genera! surgical procedure. | 11-24-2011 |
20110288044 | Modulation of sodium channels by nicotinamide adenine dinucleotide - The present invention relates to the use of oxidized nicotinamide adenine dinucleotide (NAD | 11-24-2011 |
20110301111 | CYCLIC ADENOSINE MONOPHOSPHATES FOR REDUCING THE FORMATION OF ADHESIONS - Provided herein are methods of reducing adhesion formation in a subject, for example, post-surgical abdominal and pelvic adhesions. The methods comprise administering to the subject a compound chosen from one or both of 2′,3′ cyclic adenosine monophosphate, or an analogue or pharmaceutically acceptable salt thereof, able to reduce the formation of adhesions in a subject as compared to adenosine monophosphate, wherein the 2′,3′ cyclic adenosine monophosphate, or analogue or pharmaceutically acceptable salt thereof, is administered to the subject in an amount effective to reduce adhesions in the subject. | 12-08-2011 |
20120108531 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION - Disclosed herein are novel phosphonate nucleosides and thiophosphonate nucleosides comprising a phosphonalkoxy-substituted or phosphonothioalkyl-substituted five-membered, saturated or unsaturated, oxygen-containing or sulfur-containing ring coupled to a heterocyclic nucleobase such as a pyrimidine or purine base. The invention further relates to compounds having HIV (Human Immunodeficiency Virus) replication inhibiting properties and to compounds having antiviral activities with respect to other viruses. The invention also relates to methods for preparation of all such compounds and pharmaceutical compositions comprising them. The invention further relates to the use of said compounds as a medicine and in the manufacture of a medicament useful for the treatment of subjects suffering from HIV infection, as well as for treatment of other viral, retroviral or lentiviral infections and to the treatment of animals suffering from FIV, viral, retroviral or lentiviral infections. | 05-03-2012 |
20120157403 | BICYCLIC AND TRICYCLIC DERIVATIVES AS THROMBIN RECEPTOR ANTAGONISTS - Heterocyclic-substituted tricyclics of the formula | 06-21-2012 |
20120165286 | CYCLIC NUCLEOTIDE ANALOGS - Disclosed herein are cyclic nucleotide analogs, methods of synthesizing cyclic nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with cyclic nucleotide analogs. | 06-28-2012 |
20120184503 | NUTRITIONAL COMPOSITIONS COMPRISING HUMAN MILK OLIGOSACCHARIDES AND NUCLEOTIDES AND USES THEREOF FOR TREATING AND/OR PREVENTING ENTERIC VIRAL INFECTION - Disclosed are nutritional compositions including human milk oligosaccharides and nucleotides that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases. | 07-19-2012 |
20120184504 | "The Use of a PAR-1 Antagonist in Combination with a P2Y12 ADP Receptor Antagonist for Inhibition of Thrombosis" - The treatment and prevention of thrombotic events are provided through co-administration of PAR-1 and the P2Y12 ADP receptor antagonists. Combined inhibition of the PAR-1 and the P2Y12 ADP platelet activation pathways had synergistic antithrombotic and antiplatelet effects, as demonstrated in co-administration of SCH 602539 and cangrelor. | 07-19-2012 |
20120190638 | METHODS OF TREATING HEMATOLOGIC CANCERS - This disclosure relates to the treatment of hematologic cancers, for example, cancers of the blood, by methods that include administration of EGCG and at least one of a purine nucleoside analog and an alkylating agent. In particular, methods of treating chronic lymphocytic leukemia (CLL) and acute lymphocytic leukemia (ALL) are described. | 07-26-2012 |
20120264708 | Method For Treatment Of Macular Degeneration By Modulating P2Y12 or P2X7 Receptors - Provided is a method of treating or preventing age-related macular degeneration (AMD) in a patient subject to, or symptomatic of the disease, wherein the method comprises restoring normal lysosomal pH (pH | 10-18-2012 |
20120270830 | NUTRITIONAL COMPOSITIONS INCLUDING THEANINE AND EXOGENOUS NUCLEOTIDES - Nutritional compositions and methods of making and using the nutritional compositions are provided. In a general embodiment, the present disclosure provides a nutritional composition including theanine and one or more exogenous nucleotides. The nutritional compositions can be specifically used to treat functional bowel disorders, including inflammatory bowel syndrome. | 10-25-2012 |
20120302519 | MULTIPLE SUBSTITUTED FLUOROMETHANES AS SELECTIVE AND BIOACTIVE ISOSTERES - Disclosed herein are substituted fluoromethanes; pharmaceutical compositions comprising a therapeutically effective amount of the same; processes for preparing these fluoromethanes; and methods of using the same in alleviating infection and parasitism. Also disclosed are methods for identifying substituted fluoromethanes for modulating the activity of receptors and enzymes that bind and/or modify phosphate containing ligands and substrates. | 11-29-2012 |
20130018011 | METHOD OF TREATING DENGUE FEVER - The application provides methods for treatment or prophylaxis of dengue virus mediated diseases with compounds of Formula I | 01-17-2013 |
20130040908 | SUBSTITUTION DERIVATIVES OF N6-BENZYLADENOSINE-5' -MONOPHOSPHATE, METHODS OF PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, AND THERAPEUTIC PREPARATIONS CONTAINING THESE COMPOUNDS - Substitution derivatives of N | 02-14-2013 |
20130053338 | Use of P2X Purinergic Receptor Agonists to Enhance Insulin Secretion in Pancreatic Beta Cells - Pharmaceutical compositions containing P2X purinergic agonists, e.g. P2X3 agonists, for increasing insulin secretion in a subject, methods of use, and methods of screening for related compounds and agents. | 02-28-2013 |
20130065850 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS - Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated. | 03-14-2013 |
20130090301 | AGENT FOR SUPPRESSING THE FORMATION OF ABNORMAL SKIN CELLS CAUSED BY EXPOSURE TO LIGHT - An object of the present invention is to provide an agent for suppressing the formation of skin cells induced by exposure to light such as ultraviolet light. The object is achieved by using a purine nucleic acid for suppressing the formation of abnormal skin cells caused by exposure to light. | 04-11-2013 |
20130165399 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, CONTAINING ADENOSINE N1-OXIDE AS AN EFFECTIVE INGREDIENT - The present invention has an object to provide an effective and safe therapeutic agent for inflammatory diseases such as sepsis, hepatitis, and inflammatory bowel disease, and solves the above object by providing a therapeutic agent for inflammatory diseases containing adenosine N1-oxide or a derivative thereof as an effective ingredient. | 06-27-2013 |
20130178440 | COMPOSITIONS AND METHODS FOR TREATING SKIN CANCER ASSOCIATED DISEASES - The invention provides compositions and methods for treating skin cancer associated diseases. Specifically, the invention relates to topically administering a signaling pathway inhibitor or a related compound to treat pre-cancerous skin lesions, skin tumors, and their associated diseases or disorders. | 07-11-2013 |
20130210757 | DOUBLE-LIVER-TARGETING PHOSPHORAMIDATE AND PHOSPHONOAMIDATE PRODRUGS - This application discloses phosphoramidate and phosphonoamidate prodrugs of alcohol-based therapeutic agents, such as nucleosides, nucleotides, acyclonucleosides, C-nucleosides, and C-nucleotides, and use of these prodrugs for treatment of diseases or disorders, including infectious diseases and cancers. This application also discloses a general method for enhancing bioavailability and/or liver-targeting property of alcohol drugs through converting the alcohol drugs to phosphoramidate or phosphonoamidate prodrugs, and methods of preparation of these prodrugs. | 08-15-2013 |
20130217644 | Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate] - Provided herein are pharmaceutical compositions, and in particular, oral pharmaceutical compositions, and methods of using these pharmaceutical compositions in the treatment of viral infections, including hepatitis C virus infections in hosts in need thereof. In certain embodiments, pharmaceutical compositions of 2′-C-methyl-guanosine, 5′-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl N-(phenylmethyl)phosphoramidate] are provided which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. | 08-22-2013 |
20130237492 | USE OF 2',5'-OLIGOADENYLATE DERIVATIVE COMPOUNDS - The invention relates to the therapeutic uses of 2′,5′-oligoadenylate derivative compounds, more particularly for the treatment of chronic fatigue syndrome (CFS) and in the treatment of infection by a gamma-retrovirus. | 09-12-2013 |
20130303477 | Maintenance of Platelet Inhibition During Antiplatelet Therapy - A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding. | 11-14-2013 |
20130316968 | Maintenance of Platelet Inhibition During Antiplatelet Therapy - A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding. | 11-28-2013 |
20130324492 | Maintenance of Platelet Inhibition During Antiplatelet Therapy - A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding. | 12-05-2013 |
20140080781 | Composition of HMB and ATP and Methods of Use - The present invention provides a composition comprising HMB and ATP. Methods of administering HMB and ATP to an animal are also described. HMB and ATP are administered to increase power and strength. The combination of HMB and ATP together has a synergistic effect, which results in a surprising and unexpected level of improvement in power and strength. HMB and ATP are also administered to increase lean body mass and muscle hypertrophy and to prevent typical declines in performance that are characteristic of overreaching. | 03-20-2014 |
20140088033 | NEW BORANOPHOSPHATE ANALOGUES OF CYCLIC NUCLEOTIDES - The present invention relates to novel boranophosphate analogues of cyclic nucleotides. The invention further relates to the use of such compounds as reagents for signal transduction research or as modulators of cyclic nucleotide-regulated binding proteins and isoenzymes thereof, and/or as hydrolysis- and oxidation-resistant ligands for affinity chromatography, for antibody production or for diagnostic applications e.g. on chip surfaces and/or as additive for organ transplantation storage solutions. | 03-27-2014 |
20140100186 | METHOD TO IMPROVE ANTIVIRAL ACTIVITY OF NUCLEOTIDE ANALOGUE DRUGS - A method of modifying a nucleotide or a nucleotide analogue to increase its overall effectiveness in treating an antiviral disease is provided. In some cases, a compound comprising a base, sugar, phosphonate moiety, and amino acid residue is provided, where the base-sugar may be a nucleoside, and the amino acid residue may be a tyrosine residue. In certain cases, the tyrosine residue contains a long chain alkyl group on the carboxamide group of the residue. Methods of inhibiting viral replication and methods of treating a viral infection are also provided. | 04-10-2014 |
20140107060 | Fused Pentacyclic Polyethers - Disclosed are polycyclic polyether compounds of formula I and pharmaceutical compositions comprising such compounds. | 04-17-2014 |
20140155345 | BIOTINYLATED COMPOUNDS - The invention provides new biotinylated compounds and methods for their use. | 06-05-2014 |
20140179627 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF - Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs. | 06-26-2014 |
20140235564 | METHODS FOR TREATING NEURAL CELL SWELLING - A composition comprising a novel Ca | 08-21-2014 |
20140235565 | N-ALKYLTHIO BETA-LACTAMS, ALKYL-COENZYME A ASYMMETRIC DISULFIDES, AND ARYL-ALKYL DISULFIDES AS ANTI-BACTERIAL AGENTS - The present invention provides N-alkylthio β-lactams and disulfide compounds (e.g., alkyl-coenzyme A asymmetric disulfides or aryl-alkyl disulfides), compositions containing such compounds, and methods of their use as anti-bacterial agents. | 08-21-2014 |
20140274937 | METHODS OF TREATING HEMATOLOGIC CANCERS - This disclosure relates to the treatment of hematologic cancers, for example, cancers of the blood, by methods that include administration of EGCG and at least one of a purine nucleoside analog and an alkylating agent. In particular, methods of treating chronic lymphocytic leukemia (CLL) and acute lymphocytic leukemia (ALL) are described. | 09-18-2014 |
20140288019 | Phosphorylated A2A Receptor Agonists - A phosphorylated A | 09-25-2014 |
20140296177 | NOVEL ANTIMICROBIAL COMPOUNDS - A new class of biotin protein ligase (BPL) inhibitors that have antibacterial activity against multiple | 10-02-2014 |
20140315849 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, CONTAINING ADENOSINE N1-OXIDE AS AN EFFECTIVE INGREDIENT - The present invention has an object to provide an effective and safe therapeutic agent for inflammatory diseases such as sepsis, hepatitis, and inflammatory bowel disease, and solves the above object by providing a therapeutic agent for inflammatory diseases containing adenosine N1-oxide or a derivative thereof as an effective ingredient. | 10-23-2014 |
20140336142 | Method For Treatment Of Macular Degeneration By Modulating P2Y12 or P2X7 Receptors - Provided is a method of treating or preventing age-related macular degeneration (AMD) in a patient subject to, or symptomatic of the disease, wherein the method comprises restoring normal lysosomal pH (pH | 11-13-2014 |
20140378408 | NUCLEOSIDE 5'-PHOSPHOROTHIOATE ANALOGUES AND USES THEREOF - Particular nucleoside 5′-phosphorothioate analogues, such as, adenosine or uridine 5′-di- or tri-phosphorothioate analogues in which at least one of the bridging oxygen atoms of the phosphorothioate is replaced by a group such as —CH | 12-25-2014 |
20150011497 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF - Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a norovirus, with a nucleoside, a nucleotide and an analog thereof. | 01-08-2015 |
20150011498 | USE OF A REDUCED CALORIE INFANT FORMULA CONTAINING NUCLEOTIDES AND/OR CAROTENOIDS FOR REDUCING ADVERSE HEALTH EFFECTS LATER IN LIFE - The present disclosure is directed to reduced calorie infant formulas, and in particular, reduced calorie infant formulas that have at least one nucleotide and/or at least one carotenoid for reducing inflammation-related diseases later in life. Particularly, the reduced calorie infant formulas reduce the risk of obesity later in life. | 01-08-2015 |
20150018300 | COMPOUNDS - Disclosed herein are 2′-spiro-nucleosides and derivatives thereof useful for treating a subject infected by hepatitis C virus or dengue virus. | 01-15-2015 |
20150025032 | Composition for the management of nausea and vomiting - A pharmaceutical dosage system comprising (a) an effective amount of one or more of Doxylamine, an analog thereof, a derivative thereof, a prodrug thereof, a metabolite thereof and/or a salt thereof; (b) an effective amount of one or more of (i) Pyridoxine, (ii) an analog thereof, (iii) a derivative thereof, (iv) a prodrug thereof, (v) a metabolite thereof and (vi) a salt of any of (i)-(v); and (c) an effective amount of one or more compounds of formula (I) | 01-22-2015 |
20150025033 | Composition for the management of nausea and vomiting - A pharmaceutical dosage system comprising (a) an effective amount of one or more of Doxylamine, an analog thereof, a derivative thereof, a prodrug thereof, a metabolite thereof and/or a salt thereof; (b) an effective amount of one or more of (i) Pyridoxine, (ii) an analog thereof, (iii) a derivative thereof, (iv) a prodrug thereof, (v) a metabolite thereof and (vi) a salt of any of (i)-(v); and (c) an effective amount of one or more compounds of formula (I) | 01-22-2015 |
20150038449 | Maintenance of Platelet Inhibition During Antiplatelet Therapy - A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding. | 02-05-2015 |
20150045318 | COMPONENT AND METHOD FOR TREATING VIRAL DISEASE - A method for treating viral infection includes administering to a subject in need thereof a composition containing P2X receptor antagonists. The methods may achieve preventive or therapeutic effect on hand foot and mouth disease by inhibiting viruses. The P2X receptor antagonists can inhibit infection by a positive-sense single-stranded RNA picornavirus. The virus may be an enterovirus or a Coxsackie virus, such as human enterovirus 71. The P2X receptor antagonist may be PPADS, iso-PPADS, PPNDS, Suramin, NF023, TNP-ATP, NF279, NF157, Evans Blue, an analog thereof, a derivative thereof, or a pharmaceutically acceptable salt thereof. | 02-12-2015 |
20150099716 | Maintenance of Platelet Inhibition During Antiplatelet Therapy - A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding. | 04-09-2015 |
20150105341 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF - Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Picornavirus and/or Flaviviridae infection with one or more nucleosides, nucleotides and nucleotide analogs. | 04-16-2015 |
20150119352 | DINUCELOSIDE POLYPHOSPHATES FOR THE TREATMENT OF PAIN - The invention provides a dinucleoside polyphosphate analogue, or a pharmaceutically acceptable salt thereof, for use in the inhibition (or down-regulation) of a pain, via a transducing ATP-gated P2X3 receptor, often by means of high-affinity desensitisation (HAD) mechanism. | 04-30-2015 |
20150297508 | Topical Formulation to Enhance Genital Sensation and Function - A topical formulation that functions to enhance genital sensation and function can be utilized by either male or female users. The topical formulation incorporates active compounds which function cooperatively to stimulate nerve activity, enhancing sensitivity, and facilitating tumescence in order to increase pleasure from physical stimulation and orgasms. It has incorporated various compounds that provide energy and support energy production in a cell, that stimulate nerve activity and sensitivity, that support blood flow and/or vasodilation to a bodily region, that support penetration and transport of active compounds, and that preserve the efficaciousness, effectively dilute, serve as a carrier. | 10-22-2015 |
20150297623 | METHODS FOR TREATMENT OF PRIMARY CANCER AND CANCER METASTASIS - Embodiments of the invention are directed to administering a therapeutically effective amount of a purinergic P2 receptor agonist alone or in combination with adenosine receptor antagonist and/or other anti-cancer therapies for the treatment of cancer. Agonist for the P2 receptors include non-hydrolysable ATP analogs. In particular aspects the cancer is a metastatic cancer, such as a bone metastasis. | 10-22-2015 |
20150315228 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF - Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. | 11-05-2015 |
20150328242 | IR-B Proprietary Blend - The present invention provides methods of preventing insulin resistance including administering to a subject in need thereof an effective amount of a designated IR-B Proprietary Blend. IR-B Proprietary Blend can be used to antagonize/scavenge/reduce/diminish/blunt/inhibit/suppress reactive oxygen radicals (ROS). IR-B Proprietary Blend can be used to support/help/promote/enhance gene transcription. IR-B Proprietary Blend can be used to promote/improve/stimulate/enhance/amplify microcirculation. Insulin resistance or metabolic disorders that can be prevented by using the present invention include diabetes, hyperglycemia, insulin resistance, hyperinsulinemia, obesity, atherosclerosis, heart attack, stroke, hyperlipidemia and hyperlipoproteinemia, and accelerated aging. | 11-19-2015 |
20150366888 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF - Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Coronaviridae virus, a Togaviridae virus, a Hepeviridae virus and/or a Bunyaviridae virus infection with one or more nucleosides, nucleotides and nucleotide analogs. | 12-24-2015 |
20160038527 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS - The present invention provides compositions methods for treating susceptible viral infections, especially hepatitis C viral (HCV) infections as well as co infections of HCV with other viruses such as HBV and/or HIV. In one embodiment, the present invention provides compositions having the formula (I) and their use in treating viral infections: | 02-11-2016 |
20160046661 | RAS INHIBITORS AND USES THEREOF - Described herein are compounds of Formulae (I)-(II), and pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases such as cancers (e.g., lung cancer, large bowel cancer, pancreas cancer, biliary tract cancer, or endometrial cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases in a subject. | 02-18-2016 |
20160060287 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS - The present invention discloses compounds of formula (I): | 03-03-2016 |
20160136196 | Methods for Treating Pulmonary Hypertension - The present invention relates to methods for treating or preventing pulmonary hypertension, reducing mortality in a subject experiencing pulmonary hypertension, or inhibiting ADP-mediated vasoconstriction of pulmonary arteries in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a reversible P2Y | 05-19-2016 |
20160143892 | Composition for the Management of Nausea and Vomiting - A pharmaceutical dosage system comprising (a) an effective amount of one or more of Doxylamine, an analog thereof, a derivative thereof, a prodrug thereof, a metabolite thereof and/or a salt thereof; (b) an effective amount of one or more of (i) Pyridoxine, (ii) an analog thereof, (iii) a derivative thereof, (iv) a prodrug thereof, (v) a metabolite thereof and (vi) a salt of any of (i)-(v); and (c) an effective amount of one or more compounds of formula (I) wherein R is H, PO | 05-26-2016 |
20160168186 | Method of Treating Dengue Fever | 06-16-2016 |
20160193179 | Treatment of Cardiovascular Risk in Diabetic Patients | 07-07-2016 |
20160199400 | PHARMACEUTICAL FORMULATIONS COMPRISING HIGH PURITY CANGRELOR AND METHODS FOR PREPARING AND USING THE SAME | 07-14-2016 |